JP2022529642A5 - - Google Patents
Info
- Publication number
- JP2022529642A5 JP2022529642A5 JP2021561601A JP2021561601A JP2022529642A5 JP 2022529642 A5 JP2022529642 A5 JP 2022529642A5 JP 2021561601 A JP2021561601 A JP 2021561601A JP 2021561601 A JP2021561601 A JP 2021561601A JP 2022529642 A5 JP2022529642 A5 JP 2022529642A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- pharmaceutically acceptable
- acceptable salt
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962834671P | 2019-04-16 | 2019-04-16 | |
| US62/834,671 | 2019-04-16 | ||
| PCT/US2020/028363 WO2020214734A1 (en) | 2019-04-16 | 2020-04-15 | Bicyclic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529642A JP2022529642A (ja) | 2022-06-23 |
| JP2022529642A5 true JP2022529642A5 (cg-RX-API-DMAC7.html) | 2023-04-19 |
| JP7653362B2 JP7653362B2 (ja) | 2025-03-28 |
Family
ID=72838396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021561601A Active JP7653362B2 (ja) | 2019-04-16 | 2020-04-15 | 二環式化合物 |
Country Status (18)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3877356A4 (en) | 2018-11-09 | 2022-06-22 | Vivace Therapeutics, Inc. | BICYCLIC LINKS |
| AU2020257207B2 (en) | 2019-04-16 | 2026-06-04 | Vivace Therapeutics, Inc. | Bicyclic compounds |
| CN115279368B (zh) * | 2019-11-20 | 2024-05-24 | 维瓦斯治疗公司 | 杂芳基化合物 |
| US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| WO2022120355A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
| BR112023014751A2 (pt) | 2021-01-25 | 2023-10-03 | Ikena Oncology Inc | Combinação de um inibidor de tead de 3-(imidazol-4-il)-4-(amino)-benzenossulfonamida com um inibidor de egfr e/ou inibidor de mek para uso no tratamento de câncer de pulmão |
| EP4284380A4 (en) * | 2021-01-26 | 2024-12-18 | The United States Government as represented by the Department of Veterans Affairs | COMPOSITIONS AND METHODS FOR INHIBITING YAP |
| US12655150B2 (en) | 2021-03-26 | 2026-06-16 | Cedilla Therapeutics, Inc. | TEAD inhibitors and uses thereof |
| AU2022258968A1 (en) | 2021-04-16 | 2023-10-19 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| CN117956996A (zh) * | 2021-05-11 | 2024-04-30 | Opna 生物公司 | 用于yap/tead调节的化合物和方法及其适应证 |
| AR125921A1 (es) * | 2021-05-19 | 2023-08-23 | Genentech Inc | Terapia de combinación |
| WO2022272036A1 (en) * | 2021-06-25 | 2022-12-29 | Cedilla Therapeutics, Inc. | Tead inhibitors and uses thereof |
| WO2023057371A1 (en) | 2021-10-04 | 2023-04-13 | Basilea Pharmaceutica International Ag, Allschwil | 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer |
| WO2023060227A1 (en) | 2021-10-07 | 2023-04-13 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| AU2023211607A1 (en) * | 2022-01-28 | 2024-08-22 | Opna Bio SA | Compounds and methods for yap/tead modulation and indications therefor |
| WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| JP2025513725A (ja) * | 2022-03-22 | 2025-04-30 | スポロス バイオディスカバリー,インク. | Tead阻害剤および使用方法 |
| CN119768393A (zh) | 2022-05-25 | 2025-04-04 | 医肯纳肿瘤学公司 | Mek抑制剂和其用途 |
| IL318203A (en) * | 2022-07-12 | 2025-03-01 | Adama Makhteshim Ltd | Process for preparing modified benzamides |
| CN119968359A (zh) | 2022-09-29 | 2025-05-09 | 英矽智能科技知识产权有限公司 | Tead抑制剂及其使用方法 |
| WO2024092116A1 (en) | 2022-10-26 | 2024-05-02 | Ikena Oncology, Inc. | Combination of tead inhibitors and egfr inhibitors and uses thereof |
| WO2024088399A1 (zh) * | 2022-10-27 | 2024-05-02 | 勤浩医药(苏州)有限公司 | 含磷化合物、药物组合物及其应用 |
| WO2024105610A1 (en) | 2022-11-18 | 2024-05-23 | Novartis Ag | Pharmaceutical combinations and uses thereof |
| WO2024173761A1 (en) | 2023-02-17 | 2024-08-22 | Ikena Oncology, Inc. | Combinations comprising mek inhibitors for use in the treatment of cancer |
| CN120659608A (zh) | 2023-02-23 | 2025-09-16 | 诺华股份有限公司 | 用于治疗癌症的tead抑制剂和kras g12d抑制剂组合 |
| EP4669319A1 (en) | 2023-02-23 | 2025-12-31 | Novartis AG | TEAD AND HER2 INHIBITOR COMBINATIONS FOR CANCER TREATMENT |
| JP2026513205A (ja) * | 2023-03-27 | 2026-04-23 | ビバーチェ セラピューティクス,インク. | Hippo-yap経路モジュレーターの合成およびその多形体 |
| WO2024216121A1 (en) * | 2023-04-14 | 2024-10-17 | Vivace Therapeutics, Inc. | Pharmaceutical formulations and dosing schedules of a hippo-yap pathway modulator |
| TW202448857A (zh) * | 2023-05-12 | 2024-12-16 | 大陸商正大天晴藥業集團股份有限公司 | 含有芳香二並環的化合物 |
| JP2026519523A (ja) * | 2023-05-24 | 2026-06-16 | ビアクティカ セラピューティクス エービー | Teadへの結合剤としての芳香族アミドおよびそのコンジュゲート |
| WO2025034563A1 (en) * | 2023-08-04 | 2025-02-13 | Vivace Therapeutics, Inc. | Compounds and methods for treating cancer |
| WO2025101655A1 (en) * | 2023-11-08 | 2025-05-15 | Vivace Therapeutics, Inc. | Compounds for modulating yap-tead/hippo pathway |
| WO2025122956A1 (en) * | 2023-12-08 | 2025-06-12 | Vivace Therapeutics, Inc. | Combination therapy |
| TW202547484A (zh) | 2024-04-10 | 2025-12-16 | 瑞士商諾華公司 | 藥物組合及其用途 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| JP2001511813A (ja) | 1997-02-18 | 2001-08-14 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | Crfレセプターアンタゴニストおよびそれらに関連する方法 |
| EP1042295B1 (en) | 1997-12-22 | 2005-09-07 | Pharmacia & Upjohn Company LLC | 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents |
| IT1303123B1 (it) | 1998-10-13 | 2000-10-30 | Rotta Research Lab | Derivati basici di benz(e)isoindol-1-oni e pirrolo(3,4-c)chinolin-1-oni ad attivita' 5ht3 antagonista, loro preparazione ed |
| HK1045306A1 (zh) | 1999-06-03 | 2002-11-22 | Abbott Laboratories | 抑制细胞黏附的抗炎化合物 |
| AUPQ841300A0 (en) | 2000-06-27 | 2000-07-20 | Fujisawa Pharmaceutical Co., Ltd. | New aminoalcohol derivatives |
| US7067532B2 (en) | 2000-11-02 | 2006-06-27 | Astrazeneca | Substituted quinolines as antitumor agents |
| FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
| US7544699B2 (en) | 2003-08-08 | 2009-06-09 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| WO2005082865A1 (ja) | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | 縮合二環性ピリミジン誘導体 |
| JP4847459B2 (ja) * | 2005-01-25 | 2011-12-28 | 田辺三菱製薬株式会社 | ノルバリン誘導体及びその製造方法 |
| CN102351791B (zh) | 2006-01-27 | 2014-10-29 | 菲布罗根有限公司 | 使低氧诱导因子(hif)稳定的氰基异喹啉化合物 |
| US20070259960A1 (en) | 2006-02-16 | 2007-11-08 | Fibrogen, Inc. | Compounds and methods for treatment of stroke |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| WO2008023157A1 (en) | 2006-08-21 | 2008-02-28 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as m3-receptor modulators |
| AR065093A1 (es) | 2007-02-05 | 2009-05-13 | Merck Frosst Canada Ltd | Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos |
| EP2481735A1 (en) | 2007-05-09 | 2012-08-01 | Pfizer Inc. | Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials |
| ES2614269T3 (es) | 2007-08-03 | 2017-05-30 | Biotron Limited | Procedimientos y composiciones antivíricas frente a la hepatitis C |
| BRPI0819453A2 (pt) | 2007-11-28 | 2014-10-07 | Dana Farber Cancer Inst Inc | Composto, métodos para tratar um distúrbio relacionado com atividade de cinase, para tratar câncer em um paciente, para inibir a atividade de cinase e para identificar um composto que modula a atividade de cinase de bcr-abl, composição farmacêutica, e, kit |
| EP2231156A1 (en) | 2007-12-07 | 2010-09-29 | Fibrogen, Inc. | Methods for increasing white blood cells |
| BRPI1013988A2 (pt) | 2009-04-06 | 2016-04-05 | Daiichi Sankyo Co Ltd | composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo |
| AU2010239188B2 (en) | 2009-04-22 | 2016-03-31 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| EP2588455B1 (en) | 2010-07-02 | 2018-04-04 | Gilead Sciences, Inc. | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
| KR20130140020A (ko) | 2010-10-22 | 2013-12-23 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 억제제로서의 아미노-피롤리딘-아제티딘 다이아미드 |
| CA2743391A1 (en) | 2011-05-27 | 2012-11-27 | Queen's University At Kingston | Compounds and methods for catalytic directed ortho substitution of aromatic amides and esters |
| US9278960B2 (en) | 2011-11-03 | 2016-03-08 | Merck Sharp & Dohme Corp. | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use |
| WO2013086229A1 (en) | 2011-12-07 | 2013-06-13 | Amgen Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| US20150157584A1 (en) | 2012-06-11 | 2015-06-11 | The J. David Gladstone Institutes | Inhibitors of hippo-yap signaling pathway |
| SG11201500234YA (en) | 2012-07-16 | 2015-02-27 | Fibrogen Inc | Process for making isoquinoline compounds |
| JP6113354B2 (ja) | 2013-05-03 | 2017-04-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 神経新生刺激イソキノリン誘導体 |
| US20140336182A1 (en) * | 2013-05-13 | 2014-11-13 | Amgen Inc. | Aurora Kinase Modulators and Method of Use |
| US9212182B2 (en) | 2013-06-12 | 2015-12-15 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| MX2016010056A (es) * | 2014-02-06 | 2016-11-15 | Abbvie Inc | 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. |
| JP6377245B2 (ja) | 2014-03-24 | 2018-08-22 | グアンドン ジョンシェン ファーマシューティカル カンパニー リミテッド | Smo阻害剤としてのキノリン誘導体 |
| EP3247705B1 (en) | 2015-01-20 | 2019-11-20 | Millennium Pharmaceuticals, Inc. | Quinazoline and quinoline compounds and uses thereof as nampt inhibitors |
| WO2016153948A1 (en) | 2015-03-20 | 2016-09-29 | Deuterx, Llc | Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2, 4-diones for treatment of medical disorders |
| WO2017058716A1 (en) | 2015-09-28 | 2017-04-06 | Vivace Therapeutics, Inc. | Tricyclic compounds |
| EP3156404A1 (en) | 2015-10-15 | 2017-04-19 | Inventiva | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma |
| EP3868750A1 (en) | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| US10576085B2 (en) * | 2016-04-01 | 2020-03-03 | Signal Pharmaceuticals, Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| WO2018028591A1 (zh) | 2016-08-09 | 2018-02-15 | 殷建明 | 一种喹啉衍生物及其用途 |
| US11186554B2 (en) * | 2017-05-03 | 2021-11-30 | Vivace Therapeutics, Inc. | Non-fused tricyclic compounds |
| WO2019040389A1 (en) | 2017-08-21 | 2019-02-28 | Palmese Giuseppe R | RENEWABLE FURANE AMINE CURING AGENTS FOR THERMOSETTING EPOXY PLASTIC |
| HRP20251184T1 (hr) * | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| CN112236172A (zh) | 2018-01-30 | 2021-01-15 | 福宏治疗公司 | 用于治疗病症的方法和化合物 |
| EP3877356A4 (en) | 2018-11-09 | 2022-06-22 | Vivace Therapeutics, Inc. | BICYCLIC LINKS |
| AU2020257207B2 (en) | 2019-04-16 | 2026-06-04 | Vivace Therapeutics, Inc. | Bicyclic compounds |
| US20240025913A1 (en) | 2020-10-21 | 2024-01-25 | Vivace Therapeutics, Inc. | Tertiary carboxamide compounds |
-
2020
- 2020-04-15 AU AU2020257207A patent/AU2020257207B2/en active Active
- 2020-04-15 FI FIEP20791635.4T patent/FI3956033T3/fi active
- 2020-04-15 KR KR1020217036838A patent/KR102909464B1/ko active Active
- 2020-04-15 IL IL287222A patent/IL287222B2/en unknown
- 2020-04-15 DK DK20791635.4T patent/DK3956033T3/da active
- 2020-04-15 MX MX2021012638A patent/MX2021012638A/es unknown
- 2020-04-15 BR BR112021020629A patent/BR112021020629A2/pt unknown
- 2020-04-15 US US16/849,728 patent/US11420935B2/en active Active
- 2020-04-15 PL PL20791635.4T patent/PL3956033T3/pl unknown
- 2020-04-15 EP EP20791635.4A patent/EP3956033B1/en active Active
- 2020-04-15 WO PCT/US2020/028363 patent/WO2020214734A1/en not_active Ceased
- 2020-04-15 CN CN202080044416.7A patent/CN114072207B/zh active Active
- 2020-04-15 TW TW109112690A patent/TWI849107B/zh active
- 2020-04-15 JP JP2021561601A patent/JP7653362B2/ja active Active
- 2020-04-15 CA CA3137025A patent/CA3137025A1/en active Pending
- 2020-04-15 SG SG11202111404XA patent/SG11202111404XA/en unknown
- 2020-04-15 HU HUE20791635A patent/HUE070525T2/hu unknown
- 2020-04-15 ES ES20791635T patent/ES3014444T3/es active Active
-
2022
- 2022-05-24 US US17/752,649 patent/US12103902B2/en active Active